Stock PLSH PANACEA LIFE SCIENCES HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Panacea Life Sciences Holdings, Inc.

Equities

PLSH

US69810P1093

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 09:30:00 2024-06-27 EDT 		5-day change 1st Jan Change
0.165 USD +6.45% Intraday chart for Panacea Life Sciences Holdings, Inc. -2.37% +10.00%
05-06 Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-01 Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 10.13 1.052 2.646
Enterprise Value (EV) 1 21.32 18.91 24.18
P/E ratio -2.68 x -0.11 x -0.31 x
Yield - - -
Capitalization / Revenue 4.92 x 0.65 x 1.11 x
EV / Revenue 10.4 x 11.6 x 10.1 x
EV / EBITDA -5.08 x -4.82 x -6.31 x
EV / FCF 41,953,483 x -15,705,445 x -391,028,742 x
FCF Yield 0% -0% -0%
Price to Book 1.43 x -0.49 x -0.32 x
Nbr of stocks (in thousands) 14,074 14,965 17,645
Reference price 2 0.7200 0.0703 0.1500
Announcement Date 22-03-31 23-03-30 24-04-01
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 2.198 9.018 2.06 1.627 2.385
EBITDA 1 -1.875 -3.566 -4.2 -3.921 -3.833
EBIT 1 -2.669 -5.258 -5.937 -5.652 -5.546
Operating Margin -121.42% -58.31% -288.26% -347.41% -232.55%
Earnings before Tax (EBT) 1 -2.811 -5.232 -4.782 -9.143 -8.015
Net income 1 -2.811 -5.232 -4.782 -9.143 -8.015
Net margin -127.88% -58.02% -232.2% -561.94% -336.08%
EPS 2 -0.1600 -0.2808 -0.2684 -0.6152 -0.4821
Free Cash Flow - -9.019 0.5081 -1.204 -0.0618
FCF margin - -100.01% 24.67% -73.99% -2.59%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 21-12-17 21-12-17 22-03-31 23-03-30 24-04-01
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 8.83 20 11.2 17.9 21.5
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) -4.709 x -5.595 x -2.663 x -4.553 x -5.617 x
Free Cash Flow - -9.02 0.51 -1.2 -0.06
ROE (net income / shareholders' equity) - -56.1% -69.3% -369% 154%
ROA (Net income/ Total Assets) - -10.4% -13.5% -16.3% -18.5%
Assets 1 - 50.3 35.54 56 43.32
Book Value Per Share 2 0.6700 0.3600 0.5000 -0.1400 -0.4700
Cash Flow per Share 2 0.4800 0 0 0 0.0100
Capex 1 6.98 3.2 0.16 0.24 0.07
Capex / Sales 317.53% 35.49% 7.91% 14.99% 2.74%
Announcement Date 21-12-17 21-12-17 22-03-31 23-03-30 24-04-01
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PANACEA LIFE SCIENCES HOLDINGS, INC. Stock Panacea Life Sciences Holdings, Inc.
+10.00% 3.43M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PLSH Stock
  4. Financials Panacea Life Sciences Holdings, Inc.